A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
To evaluate the efficacy and safety of CM336 (B Cell Maturation Antigen/Cluster of Differentiation 3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia
Epistemonikos ID: f75a393b0d685d28c13e55c460349017cfed13bc
First added on: Sep 17, 2025